Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Big Data and Proactive Pharmacovigilance

Posted on September 20th, 2017 by in Pharmacovigilance

Traditionally thought of as a post-market process, pharmacovigilance is how pharmaceutical companies monitor and address any safety issues that arise once a drug becomes available commercially. However, some companies are now thinking ahead about these potential safety concerns with what is known as “proactive PV”. Continue reading “Big Data and Proactive Pharmacovigilance” »

Taking a Balanced Approach to Monitoring Literature

Posted on September 11th, 2017 by in Pharmacovigilance

In a time when the focus on pharmacovigilance is greater than ever before, literature monitoring presents pharmaceutical companies with significant challenges. Pharmacovigilance groups are looking for ways to efficiently and cost-effectively manage an increasing workload while remaining compliant with regulatory best practices. Continue reading “Taking a Balanced Approach to Monitoring Literature” »

What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?

Posted on June 14th, 2017 by in Pharmacovigilance

The health and safety of patients is of utmost concern to pharmaceutical companies, and strict regulatory requirements ensure that safety standards remain high. But pharmacovigilance becomes an ever more difficult and overwhelming practice Continue reading “What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?” »

Gaining the Competitive Advantage

Posted on June 12th, 2017 by in Pharma R&D

It cannot be overstated how important it is for pharmaceutical companies to get new drugs to market as fast as possible. That some of these drugs could actually be life-saving, or at least life-altering, for hundreds, thousands or even millions of potential patients Continue reading “Gaining the Competitive Advantage” »

  1. 1
  2. 2
  3. 3
  4. 4